Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30617843 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL15795 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL346866 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL15166 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL345787 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL345385 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL346923 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL1651991 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL345903 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB | |
| SCHEMBL345072 | 1.00 | TSHR (0.62) | TSHRLPAR3LPAR2LPAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308453-B1 | PRIMER COMPOSITION FOR METAL OXIDE CERAMICS | TOKUYAMA DENTAL CORP (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8790741-B2 | Primer composition for metal oxide ceramics | TOKUYAMA DENTAL CORPORATION (JP) | 2014-07-29 | — | — | US | disclosed |
| US-20110143015-A1 | PRIMER COMPOSITION FOR METAL OXIDE CERAMICS | TOKUYAMA DENTAL CORPORATION | 2011-06-16 | — | — | US | disclosed |
| EP-2308453-A1 | PRIMER COMPOSITION FOR METAL OXIDE CERAMICS | Tokuyama Dental Corporation (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-6265508-B1 | Metal surface treatment agent having thiophenecarboxylic acid ester-containing and phosphoric acid ester-containing polymerizable monomer groups | GC CORPORATION (JP) | 2001-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110143015-A1 | PRIMER COMPOSITION FOR METAL OXIDE CERAMICS | TERT, TMCO1, MED1 | TSHR 2876/4885LPAR3 3664/4885LPAR2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.